MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
BioCardia Total Liabilities 2011-2025 | BCDA
Annual Total Liabilities BioCardia
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.59 M | 4.9 M | 5.34 M | 4.25 M | 5.31 M | 2.62 M | 2.41 M | 1.5 M | 10 K | 1 K | 18 K | 12 K | 756 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.34 M | 1 K | 2.44 M |
Quarterly Total Liabilities BioCardia
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.52 M | 3.98 M | 3.69 M | 2.89 M | 3.51 M | 4.85 M | 4.95 M | 4.59 M | 4.41 M | 4.75 M | 5.23 M | 4.9 M | 5.08 M | 4.53 M | 5.47 M | 5.34 M | 3.92 M | 4.54 M | 4.75 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | 5.31 M | 5.31 M | 5.31 M | 5.31 M | 2.62 M | 2.62 M | 2.62 M | 2.62 M | 2.41 M | 2.41 M | 2.41 M | 2.41 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 8.3 M | 10 K | 10 K | 10 K | 10 K | 1 K | 1 K | - | 1 K | 5 K | 1 K | 1 K | 12 K | 12 K | 12 K | 12 K | 756 K | 756 K | 756 K | 756 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.3 M | 1 K | 2.77 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
38.4 M | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
64.8 M | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
10.8 M | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioVie
BIVI
|
2.55 M | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 12.37 | 2.06 % | $ 814 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
570 M | - | - | $ 7.29 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Celldex Therapeutics
CLDX
|
45.3 M | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Celsion Corporation
CLSN
|
5.47 M | - | -6.63 % | $ 13.9 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
845 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
161 M | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
CorMedix
CRMD
|
11.9 M | $ 12.19 | 1.75 % | $ 621 M | USA |
 |
Cortexyme
CRTX
|
82.8 M | - | -1.05 % | $ 67.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 0.18 | -25.03 % | $ 392 M |  Israel |
 |
CTI BioPharma Corp.
CTIC
|
144 M | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
2.15 B | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
63.2 B | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |